Open Orphan PLC Intention to change name to hVIVO plc (6886Y)
September 08 2022 - 1:01AM
UK Regulatory
TIDMORPH
RNS Number : 6886Y
Open Orphan PLC
08 September 2022
Open Orphan plc
("Open Orphan" or the "Company")
Planned name change to hVIVO plc
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in testing
infectious and respiratory disease products using human challenge
clinical trials, announces its intention to change its name to
hVIVO plc, with the change expected to take effect on 26 October
2022.
The Board believes that the name change reflects the Company's
core human challenge and early clinical services business, where
the hVIVO name has strong global brand recognition within the
biopharma industry and beyond, as well as aligning the Company more
closely with its long and established heritage.
The Company's new ticker will be HVO as of 26 October 2022 and
the website address (including the investor relations content and
the information required by AIM Rule 26) will be available at
www.hvivo.com
The Company's ISIN (GB00B9275X97) and SEDOL (B9275X9) will
remain the same.
Shareholders will be unaffected by the change of name and
existing share certificates should be retained and will remain
valid. Any new share certificates issued after the name change
takes effect will bear the name hVIVO plc.
For further information please contact:
Open Orphan plc +44 (0) 20 7756 1300
Yamin Khan, Chief Executive Officer
Liberum Capital (Nominated Adviser
and Joint Broker) +44 (0) 20 3100 2000
Ben Cryer/ Edward Mansfield/ Phil
Walker/ Will King
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson / Richard
Chambers
Davy (Euronext Growth Adviser and
Joint Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Stephanie Cuthbert / Phillip +44 (0) 7796 794 663 / +44 (0) 7867 984
Marriage / 082 /
Louis Ashe-Jepson +44 (0) 7747 515 393
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is changing its name
to hVIVO plc (AIM and Euronext: HVO), which is expected to take
effect on the AIM market of the London Stock Exchange and the
Euronext Growth Exchange market on 26 October 2022.
hVIVO is a rapidly growing contract research company that is a
world leader in testing infectious and respiratory disease products
using human challenge clinical trials. The Company provides
services to Big Pharma, biotech, and government/public health
organisations.
The Company has a leading portfolio of human challenge study
models for infectious and respiratory diseases and is developing a
number of new models, such as malaria and COVID-19, to address the
dramatic growth of the global infectious disease market. The Paris
and Breda offices have over 25 years of experience providing drug
development services such as biometry, data management, statistics
CMC, PK and medical writing to third party clients as well as
supporting the London-based challenge studies.
hVIVO runs challenge studies in London from its Whitechapel
quarantine clinic, its state-of-the-art QMB clinic with its highly
specialised on-site virology and immunology laboratory, and its
newly opened clinic in Plumbers Row. To recruit volunteers /
patients for its studies, the Company leverages its unique clinical
trial recruitment capacity via its FluCamp volunteer screening
facilities in London and Manchester. The newly opened facilities
have expanded the scope of the business to enable the offering of
Phase I and Phase II vaccine field trials, PK studies, bridging
studies, and patient trials as part of large international
multi-centre studies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CANBKOBDKBKBKCK
(END) Dow Jones Newswires
September 08, 2022 02:01 ET (06:01 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Aug 2023 to Aug 2024